RUNX3 functions as a tumor suppressor in breast cancer and is frequently inactivated by promoter hypermethylation and protein mislocalization, and expression of RUNX3 has been suggested as a promising prognostic biomarker in breast cancer patients [17,23]. Here, RUNX3 is linked to neoplasm.